Dr. Kissler received his B.Sc. in Biochemistry and his Ph.D. in Immunology from the University of Bristol, UK. Following postdoctoral work at the Dana-Farber Cancer Institute in Boston and at the Massachusetts Institute of Technology in Cambridge, MA, Dr. Kissler was appointed to a group leadership at the Rudolf Virchow Center at the University of Wurzburg, Germany, in 2007. In April 2012, Dr. Kissler returned to Boston to join the section for Immunobiology at Joslin Diabetes Center, where his laboratory is studying the autoimmune attack on the pancreas that underlies Type 1 diabetes.
Stephan Kissler studied Biology at the University of Zurich, Switzerland and Biochemistry at the University of Bristol UK. Following a short stay as a research assistant at the University of Heidelberg, Germany, Kissler returned to the UK to complete a Ph.D. in Immunology with Prof. David Wraith, a leading expert in antigen-specific therapies for autoimmune disease. Dr. Kissler then worked in Harvey Cantor's laboratory at the Dana-Farber Cancer Institute in Boston, MA, continuing his research into T cells in the context of autoimmune disease. Kissler then decided to broaden his expertise and joined the laboratory of Luk van Parijs at MIT in Cambridge, MA. There, Kissler became an expert in the use of RNAi for the manipulation of gene expression in mouse models of disease. During his time at MIT, Kissler uncovered that his supervisor, van Parijs, was fabricating research data, which led to van Parijs' dismissal for research misconduct. Undeterred by this misadventure, Kissler pursued his unique research approach that combined a deep understanding of autoimmunity and experience with new genetic models of disease. His success in applying RNAi to the study of Type 1 diabetes led Kissler to be recruited to the Rudolf-Virchow Center for Experimental Biomedicine at the University of Wurzburg, Germany, a prestigious research institution where Kissler established his own research group. In 2012, Kissler returned to Boston to accept a position at Joslin Diabetes Center, where his laboratory is trying to unravel the complexity of the autoimmunity that underlies Type 1 diabetes. Most recently, Kissler also became the Co-Director of Joslin's Research Fellows Affairs and established a new mouse genome editing core facility of which he is currently the director. In addition to his research activities at Joslin, Kissler also participates in teaching at Harvard Medical School, particularly within the Graduate Program in Immunology of which Kissler is a Faculty Member.